A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia

Trial Profile

A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Anaemia; Haemorrhage
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Status changed from not yet recruiting to recruiting, according to interim results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Interim results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 13 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top